Obesity Can Improve Overall Survival in Late-stage Prostate Cancer Patients But Not Disease Outcomes, Study Finds

Obesity Can Improve Overall Survival in Late-stage Prostate Cancer Patients But Not Disease Outcomes, Study Finds
Obesity can improve overall survival in men with late-stage, castration-resistant prostate cancer, a study showed. However, obesity does not seem to change the risk of death due to prostate cancer nor the likelihood of the cancer's spread. The study, "Obese patients with castration‐resistant prostate cancer may be at a lower risk of all‐cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database," was published in the journal BJU International. Several studies support obesity being a risk factor for aggressive prostate cancer at diagnosis, and of increasing the chances of cancer recurrence and mortality after radical prostatectomy – surgery to remove the prostate gland and surrounding tissues. (Overall survival refers to a patient's death from any cause, not just cancer-related causes.) But very few studies have analyzed the influence of obesity on the outcomes of men undergoing hormone therapy, also called androgen deprivation therapy (ADT) — a treatment to lower the levels of male sex hormones, such as testosterone, with the goal of halting tumor growth. ADT is particularly indicated for patients whose cancer has spread too far to be treated with surger
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *